Vonoprazan-amoxicillin dual, rifabutin-based triple, and bismuth quadruple therapies for Helicobacter pylori rescue treatment: a multicentre, open-label, non-inferiority randomised trial
National Natural Science Foundation of China, and Xinyi Digestive Disease Fund Project, College of Digestive Sciences, Shanghai Jiao Tong University School of Medicine.
Authors
- Yixian Guo (ORCID: https://orcid.org/0000-0002-4542-4929)
- Ping Xu (ORCID: https://orcid.org/0000-0001-8692-0219)
- Jin-nan Chen
- Meixuan Li (ORCID: https://orcid.org/0000-0001-9373-4086)
- Yi-Xiang Wang (ORCID: https://orcid.org/0000-0002-4021-4228)
- Shu-Han Qiu
- Ya-Nan Gao
- Xiao Liang
- Yu Huang
- Yue-Hua Han
- Hong Lu
Institutions
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
- Tongren Hospital (CN)
- Songjiang District Central Hospital (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
Publication Details
- Journal
- The Lancet Regional Health - Western Pacific
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1016/j.lanwpc.2026.101815
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00